Who is sponsoring NCT00046371?

NCT00046371 is sponsored by Oncothyreon Canada Inc..

What condition does NCT00046371 study?

NCT00046371 studies Breast Neoplasms.

What drugs are being tested in NCT00046371?

Interventions: THERATOPE® vaccine.

What is the status of NCT00046371?

NCT00046371 is currently COMPLETED.

Last reviewed 2008-01-22 · How we verify

Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®

NCT00046371 Phase 2 COMPLETED

The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and who do not require chemotherapy. Post-menopausal women on aromatase inhibitors or Faslodex® alone and pre-menopausal women on aromatase inhibitors plus luteinising hormone-releasing hormone (LH/RH)-agonist may be eligible to be enrolled. Patients must not have had radiotherapy or major surgery within four (4) weeks prior to entering the study. Information about the safety and tolerability of administration of the THERATOPE® vaccine will also be gathered during the course of the study.

Details

Lead sponsor	Oncothyreon Canada Inc.
Phase	Phase 2
Status	COMPLETED
Start date	2002-08
Completion	2005-08

Conditions

Breast Neoplasms

Interventions

THERATOPE® vaccine

Countries

United States